糖耐量异常患者胰腺细胞外容积分数的T1 mapping评估
前瞻性纳入45例已知或疑似胰腺疾病患者,行包括T1 mapping的增强MR检查,按HbA1c分为无糖尿病、糖尿病前期和2型糖尿病三组。结果显示HbA1c与胰腺平扫T1值及ECV均正相关(r=0.79和r=0.60,P<0.001),2型糖尿病组两项指标均显著高于其他两组,ECV鉴别2型糖尿病的敏感度、特异度和AUC分别为100%、93.5%和0.990,优于平扫T1值的84.6%、96.8%和0.906。
要点
- 胰腺ECV与HbA1c正相关(r=0.60,P<0.001),或可反映胰腺纤维化。
- ECV鉴别2型糖尿病的敏感度100%、特异度93.5%、AUC 0.990。
- ECV的鉴别效能优于平扫胰腺T1值(AUC 0.906)。
关键影像表现/征象
- 2型糖尿病组胰腺平扫T1值和ECV均显著高于无糖尿病组和糖尿病前期组(P<0.001)。
- 无糖尿病组与糖尿病前期组之间胰腺平扫T1值和ECV均无显著差异(P=0.14)。
诊断标准与关键数值
- ECV鉴别无糖尿病和糖尿病前期与2型糖尿病:敏感度100%、特异度93.5%、AUC 0.990。
- 平扫胰腺T1值鉴别无糖尿病和糖尿病前期与2型糖尿病:敏感度84.6%、特异度96.8%、AUC 0.906。
- HbA1c与胰腺平扫T1值正相关(r=0.79,P<0.001),与ECV正相关(r=0.60,P<0.001)。
临床应用与阅片要点
- 作者认为胰腺ECV可能作为评估导致糖耐量异常的胰腺纤维化的潜在影像生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate pancreatic T1 mapping and extracellular volume (ECV) fraction's feasibility to assess impaired glucose tolerance (IGT) patients.
METHODS: A total of 45 consecutive patients with known or suspected pancreatic disease underwent contrast-enhanced magnetic resonance (MR) imaging, including T1 mapping, using saturation recovery sequence. Patients were classified into three groups based on the American Diabetes Association criteria: no-diabetes subjects, HbA1c < 5.7%; pre-diabetes, 5.7% ≤ HbA1c < 6.5%; and type 2 diabetes mellitus (T2DM), HbA1c ≥ 6.5%. Pre-contrast pancreatic T1 value and ECV of the pancreas were computed, and then pre-contrast pancreatic T1 value, ECV and HbA1c values were compared. The present prospective study was approved by our institutional review board. Written informed consent was obtained from all patients.
RESULTS: A positive correlation between HbA1c values and both pre-contrast pancreatic T1 value and ECV (r = 0.79, P < 0.001 and r = 0.60, P < 0.001, respectively) were observed. The pre-contrast pancreatic T1 value and ECV were significantly higher in T2DM vs. no-diabetes subjects and pre-diabetes (P < 0.001). No significant difference between two qualitative values (P = 0.14) was found, however, the sensitivity, specificity, and area under the receiver-operating-characteristic curve differentiating no-diabetes subjects and pre-diabetes from T2DM were superior in ECV (100%, 93.5%, and 0.990) vs. pre-contrast pancreatic T1 values (84.6%, 96.8%, and 0.906).
CONCLUSIONS: The ECV of the pancreas could serve as a potential imaging biomarker for the assessment of pancreatic fibrosis leading to IGT.
引用
- Noda Y, Goshima S, Tsuji Y, et al. Pancreatic extracellular volume fraction using T1 mapping in patients with impaired glucose intolerance. Abdom Radiol (NY). 2020. PMID: 31894382. doi:10.1007/s00261-019-02384-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。